Literature DB >> 19705385

Synthesis and structure-activity relationships of allosteric potentiators of the m(4) muscarinic acetylcholine receptor.

J Phillip Kennedy1, Thomas M Bridges, Patrick R Gentry, John T Brogan, Alexander S Kane, Carrie K Jones, Ashley E Brady, Jana K Shirey, P Jeffrey Conn, Craig W Lindsley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19705385      PMCID： PMC2887613          DOI： 10.1002/cmdc.200900231

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  17 in total

Review 1.  Therapeutic opportunities for muscarinic receptors in the central nervous system.

Authors:  C C Felder; F P Bymaster; J Ward; N DeLapp
Journal:  J Med Chem       Date:  2000-11-16       Impact factor: 7.446

2.  Discovery of an ectopic activation site on the M(1) muscarinic receptor.

Authors:  Tracy A Spalding; Carol Trotter; Niels Skjaerbaek; Terri L Messier; Erika A Currier; Ethan S Burstein; Donghui Li; Uli Hacksell; Mark R Brann
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

Review 3.  Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system.

Authors:  Frank P Bymaster; David L McKinzie; Christian C Felder; Jürgen Wess
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 4.  Keynote review: histamine H3 receptor antagonists reach out for the clinic.

Authors:  Sylvain Celanire; Maikel Wijtmans; Patrice Talaga; Rob Leurs; Iwan J P de Esch
Journal:  Drug Discov Today       Date:  2005-12       Impact factor: 7.851

Review 5.  Muscarinic receptors--characterization, coupling and function.

Authors:  M P Caulfield
Journal:  Pharmacol Ther       Date:  1993-06       Impact factor: 12.310

6.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

7.  Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; A C Young; M R Brann; N J Buckley
Journal:  Neuron       Date:  1988-07       Impact factor: 17.173

8.  Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.

Authors:  Carrie K Jones; Ashley E Brady; Albert A Davis; Zixiu Xiang; Michael Bubser; Mohammed Noor Tantawy; Alexander S Kane; Thomas M Bridges; J Phillip Kennedy; Stefania R Bradley; Todd E Peterson; M Sib Ansari; Ronald M Baldwin; Robert M Kessler; Ariel Y Deutch; James J Lah; Allan I Levey; Craig W Lindsley; P Jeffrey Conn
Journal:  J Neurosci       Date:  2008-10-08       Impact factor: 6.167

Review 9.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

10.  Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.

Authors:  Ashley E Brady; Carrie K Jones; Thomas M Bridges; J Phillip Kennedy; Analisa D Thompson; Justin U Heiman; Micah L Breininger; Patrick R Gentry; Huiyong Yin; Satyawan B Jadhav; Jana K Shirey; P Jeffrey Conn; Craig W Lindsley
Journal:  J Pharmacol Exp Ther       Date:  2008-09-04       Impact factor: 4.030
View more
  21 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 2.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

3.  Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.

Authors:  Bruce J Melancon; Michael R Wood; Meredith J Noetzel; Kellie D Nance; Eileen M Engelberg; Changho Han; Atin Lamsal; Sichen Chang; Hyekyung P Cho; Frank W Byers; Michael Bubser; Carrie K Jones; Colleen M Niswender; Michael W Wood; Darren W Engers; Dedong Wu; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-04-13       Impact factor: 2.823

4.  Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule.

Authors:  Bruce J Melancon; Michael S Poslusney; Patrick R Gentry; James C Tarr; Douglas J Sheffler; Margrith E Mattmann; Thomas M Bridges; Thomas J Utley; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

5.  Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse and Parkinson's Disease.

Authors:  Ditte Dencker; Morgane Thomsen; Gitta Wörtwein; Pia Weikop; Yinghong Cui; Jongrye Jeon; Jürgen Wess; Anders Fink-Jensen
Journal:  ACS Chem Neurosci       Date:  2012       Impact factor: 4.418

6.  Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.

Authors:  James M Salovich; Paige N Vinson; Douglas J Sheffler; Atin Lamsal; Thomas J Utley; Anna L Blobaum; Thomas M Bridges; Uyen Le; Carrie K Jones; Michael R Wood; J Scott Daniels; P Jeffrey Conn; Colleen M Niswender; Craig W Lindsley; Corey R Hopkins
Journal:  Bioorg Med Chem Lett       Date:  2012-06-06       Impact factor: 2.823

7.  Novel M4 positive allosteric modulators derived from questioning the role and impact of a presumed intramolecular hydrogen-bonding motif in β-amino carboxamide-harboring ligands.

Authors:  Michael S Poslusney; James M Salovich; Michael R Wood; Bruce J Melancon; Katrina A Bollinger; Vincent B Luscombe; Alice L Rodriguez; Darren W Engers; Thomas M Bridges; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-12-18       Impact factor: 2.823

8.  Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.

Authors:  Michael R Wood; Meredith J Noetzel; James C Tarr; Alice L Rodriguez; Atin Lamsal; Sichen Chang; Jarrett J Foster; Emery Smith; Peter Chase; Peter S Hodder; Darren W Engers; Colleen M Niswender; Nicholas J Brandon; Michael W Wood; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-07-21       Impact factor: 2.823

9.  Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.

Authors:  Thomas M Bridges; J Phillip Kennedy; Hyekyung P Cho; Micah L Breininger; Patrick R Gentry; Corey R Hopkins; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

10.  Malignant synaptic growth and Alzheimer's disease.

Authors:  Ehren L Newman; Christopher F Shay; Michael E Hasselmo
Journal:  Future Neurol       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.